SCHEMBL568129

SCHEMBL568129

CCC(=O)c1cc(Br)no1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA4 P43681 2/20 0.43
POLB P06746 1/20 0.39
HCAR2 Q8TDS4 1/20 0.38
SMPD1 P17405 1/20 0.36
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
CYP3A4 P08684 1/20 0.35
PTGS1 P23219 1/20 0.35
DRD3 P35462 1/20 0.35
RAB9A P51151 3/20 0.34
NPC1 O15118 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
ALDH1A1 P00352 1/20 0.33
TP53 P04637 1/20 0.33
MAPK1 P28482 1/20 0.33
GAA P10253 1/20 0.33
ATM Q13315 1/20 0.33
HSP90AB1 P08238 1/20 0.32
ADRB2 P07550 3/20 0.32
ADRB1 P08588 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6074169 0.84 CHRNA4 (0.43) CHRNA4POLBHCAR2RAB9ASMN1; SMN2
SCHEMBL1641444 0.79
SCHEMBL3465251 0.78 CHRNA4 (0.36) CHRNA4POLBADRB2ADRB1ADRB3
SCHEMBL368680 0.78 ALDH1A1 (0.43) CHRNA4POLBKMT2AMEN1RAB9A
SCHEMBL10072233 0.78 HCAR2 (0.64) CHRNA4POLBHCAR2KMT2AMEN1
SCHEMBL568672 0.77
SCHEMBL10520059 0.77 CHRNA4 (0.38) CHRNA4POLBHCAR2SMPD1RAB9A
SCHEMBL27864778 0.76 POLB (0.39) POLBHCAR2SMPD1KMT2AMEN1
SCHEMBL9819411 0.75
Hydrochloric Acid SCHEMBL10999756 0.75 HCAR2 (0.55) CHRNA4POLBHCAR2KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2346868-B1 AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2016-01-27 EP disclosed
EP-2346868-B1 AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2016-01-27 EP disclosed
US-8338610-B2 Pyridinyl compounds useful as intermediates BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-12-25 US disclosed
US-8338610-B2 Pyridinyl compounds useful as intermediates BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-12-25 US disclosed
US-8338610-B2 Pyridinyl compounds useful as intermediates BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-12-25 US disclosed
US-20120136158-A1 Pyridinyl Compounds Useful As Intermediates BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-31 US disclosed
US-20120136158-A1 Pyridinyl Compounds Useful As Intermediates BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-31 US disclosed
US-20120136158-A1 Pyridinyl Compounds Useful As Intermediates BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-31 US disclosed
US-8163918-B2 Azaindazole compounds as CCR1 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-24 US disclosed
US-8163918-B2 Azaindazole compounds as CCR1 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-24 US disclosed
WO-2010036632-A1 AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-01 WO disclosed
US-5602160-A MUSCLE RELAXANT MITSUI TOATSU CHEMICALS INCORPORATED (JP) 1997-02-11 US disclosed
US-5498619-A MUSCLE RELAXANTS, POLLAKIUREA CURING AGENTS AND MUSCLE SPASMS MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1996-03-12 US disclosed
EP-0414391-B1 Aminoketone derivatives and use thereof MITSUI TOATSU CHEMICALS (JP) 1995-03-15 EP disclosed
US-5338857-A Muscle relaxant MITSUI TOATSU CHEMICALS INCORPORATED (JP) 1994-08-16 US disclosed
EP-0414391-A2 Aminoketone derivatives and use thereof MITSUI TOATSU CHEMICALS, Inc. (JP) 1991-02-27 EP disclosed
EP-0207955-B1 PROCESS FOR THE PREPARATION OF 3,5-DISUBSTITUTED ISOXAZOLES ZAMBON S.p.A. (IT) 1990-02-07 EP disclosed
US-4772719-A FROM DIHALOFORMALDOXIME AND ALKYNE, CYCLIZATION ZAMBON S.P.A. (IT) 1988-09-20 US disclosed
EP-0207955-A1 PROCESS FOR THE PREPARATION OF 3,5-DISUBSTITUTED ISOXAZOLES. ZAMBON SPA (IT) 1987-01-14 EP disclosed
WO-1986003490-A1 PROCESS FOR THE PREPARATION OF 3,5-DISUBSTITUTED ISOXAZOLES ZAMBON S.P.A. (IT) 1986-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136158-A1 Pyridinyl Compounds Useful As Intermediates CCR1, CCRL2, CCR4 CHRNA4 1537/4885POLB 1195/4885HCAR2 216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.